MedTrace Logo

Bupropion and Restless Legs Syndrome

NCT00621517 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-03-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if bupropion will improve the symptoms of restless legs syndrome (RLS).

Conditions

  • Restless Legs Syndrome

Interventions

DRUG

Bupropion

Partipants will receive 150 mg bupropion per night

DRUG

Placebo

1 capsule nightly for six weeks

Sponsors & Collaborators

  • East Tennessee State University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00621517 on ClinicalTrials.gov